Category Archives: Pharmaceuticals

Monoclonal Antibody Industry for Global & China Markets Forecasts to 2017 in New Research Report at

Monoclonal Antibody Industry for Global & China Markets Forecasts to 2017 in New Research Report at

Dallas, TX (PRWEB) December 24, 2013

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.


Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).

Continue reading “Monoclonal Antibody Industry for Global & China Markets Forecasts to 2017 in New Research Report at” »

Nucleus Medical Media Supports Cervical Health Awareness Month with Complimentary 3D Animations

Nucleus Medical Media Supports Cervical Health Awareness Month with Complimentary 3D Animations

Atlanta, GA (PRWEB) January 07, 2014

As medical organizations recognize January as Cervical Health Awareness Month, Nucleus Medical Media offers informational medical animations at no charge through social media channels to explain and promote health literacy.

According to the most recent data from the CDC, almost 12,000 women in the United States were diagnosed with cervical cancer in 2010. Though the number of deaths from cervical cancer has decreased drastically since the increased use of the Pap test beginning in the 1950s, other measures can help prevent the disease before a cancer diagnosis.

Lynn B. Barclay, the President and CEO of the National Cervical Cancer Coalition, says, “Cervical cancer is preventable through vaccines and screening tests. Making sure these tools reach the most vulnerable women is critical, of course, but so are efforts to educate women about the disease. Accurate, culturally-sensitive information and access to care are an unbeatable combination.”

With a mission to support and enhance health literacy, Nucleus offers free, informational videos about cervical health on the Nucleus Medical Media YouTube channel including the following:

    HPV: Preventing Cervical Cancer—explains how to avoid HPV and how the vaccine can prevent cervical cancer
    Cervical Cancer Symptoms—outlines the symptoms that could mean cervical cancer
    Cervical Cancer Staging—demonstrates what various stages of cervical center look like from inside the body
    Treatments for Cervical Cancer—explains options for treatment such as surgery, radiation therapy, and chemotherapy

Ron Collins, CEO and Co-founder of Nucleus Medical Media believes that the web is ideally suited to help spread health literacy information like cervical cancer prevention: “Health literacy is the first step in preventing diseases and conditions,” he says. “We ask all of our viewers on YouTube and Facebook to watch and share these animations to raise awareness of Cervical Health Awareness Month and how to prevent cervical cancer.”

If you are a nonprofit organization interested in using medical animations for community-based or faith-based health presentations on cervical health and cancer, email Nucleus at info(at)nucleusinc(dot)com with “Cervical Health Information” in the subject heading.

For further comment, contact Ronald Collins, CEO and Cofounder of Nucleus Medical Media, at rcollins(at)nucleusinc(dot)com or (770) 805-0460.

About Nucleus Medical Media

Founded in 1997, Nucleus Medical Media, Inc. is an award-winning creator of medical illustrations, medical animations, and interactive multimedia for the publishing, legal, healthcare, entertainment, pharmaceutical, medical device, and academic markets. Nucleus’s clients and partners include WebMD, McGraw-Hill, Dr. Oz, EBSCO Publishing, and thousands of other businesses in new and traditional media. Nucleus employs the world’s largest team of graduate-degreed medical illustrators, and has a Medical Review Board with more than 125 physicians and nurses. For more information, click here to visit our website.

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Intelligent Transport Systems (ITS) Market Will Be Worth $24.75 Billion by 2017 – New Report by MarketsandMarkets

Intelligent Transport Systems (ITS) Market Will Be Worth $ 24.75 Billion by 2017 – New Report by MarketsandMarkets

(PRWEB) December 26, 2013

According to a new market research report “Intelligent Transport Systems Market – Trends, Adoption & Worldwide Forecasts (2012 – 2017)”, the total market is expected to reach $ 24.75 billion by 2017, at a CAGR of 12% from 2012 to 2017.

Browse 128 tables spread across 287 pages and in-depth TOC on “Intelligent Transport Systems (ITS) Market”:
The term “Intelligent Transportation System” refers to the integration of the information and communication technology to improve the transportation network related to the railways, roadways, airways, and marine transport. The major focus of the government is towards the improvement of the road transportation due to the increasing number of road accidents and congestion in almost all the countries. Increasing mobilization from the rural to urban areas is one of the major reasons behind the increasing number of vehicles on the roads, which causes traffic problems as well as pollution. “ITS” is the best solution to all the problems on the road. This report covers the “Intelligent Transportation System for the road transportation”.

This report describes the various systems of ITS such as Advanced Traffic Management System (ATMS), Advanced Traveler Information System (ATIS), ITS-Enabled Transportation Pricing System, Advanced Public Transportation System (APTS) and Commercial Vehicle Operation (CVO). Out of all the above types, Advanced Traffic Management System, Advanced Public Transportation System and ITS enabled Transportation Pricing System are mostly deployed systems. The demand for the Advanced Traveler Information System is going on increasing to improve the safety and security of the travelers and drivers.

This report also covers the major applications of the ITS on the basis of the different functions performed by the various ITS systems. The major applications of ITS described in this report are fleet management and asset monitoring, traffic monitoring, collision avoidance system, traffic signal control system, variable traffic message signs, parking availability system and traffic enforcement cameras. Traffic monitoring, variable traffic message signs and traffic signal control system are the major applications of the ITS market. The application of collision avoidance system is in the niche stage in the present scenario but it is expected to grow at a rapid rate in the coming five years. The major reason behind the growth of collision avoidance system is to improve the communication technology between vehicle to vehicle and vehicle to infrastructure.

This report describes the overall market into four major geographical segments, namely, North America, Europe, APAC, and ROW. All the four major regions are further segmented into the major countries. North America is the market leader in the overall ITS market; followed by Europe and APAC. In ROW, Middle East, and Africa are the largest contributors.

Browse Related Reports:

LiDAR Market by Components (INS, Laser, GPS/GNSS, Camera, MEMS), Product Types (Airborne, Mobile, Terrestrial), Applications (Corridor Mapping, Forestry, Mining, Topographic Surveying, Volumetric Mapping) – Analysis & Forecast (2013 – 2018)

Sensors Market in Consumer Electronics by Product (Touch, Image, Motion, Temperature, Position, Pressure), Application (Entertainment, I.T., Communication Products, Home Appliances), & Geography (North America, Europe, APAC, ROW) – Worldwide Market Forecasts and Analysis (2013 – 2020)

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.


Mr. Rohan

North – Dominion Plaza

17304 Preston Road

Suite 800, Dallas, TX 75252

Tel: +1-888-600-6441

Global Atherectomy and Thrombectomy Devices Market 2014 – 2018

Global Atherectomy and Thrombectomy Devices Market 2014 – 2018

Albany, NY (PRWEB) December 24, 2013

Global Atherectomy and Thrombectomy Devices Market 2014 – 2018

Global Atherectomy and Thrombectomy Devices market is to grow at a CAGR of 9.36 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing prevalence of abdominal aortic aneurysm and peripheral artery disease. The Global Atherectomy and Thrombectomy Devices market has also been witnessing the increase in demand for minimally invasive procedures. However, the lack of awareness about peripheral vascular disease among patients could pose a challenge to the growth of this market.

To check out the complete table of contents, visit:

Global Atherectomy and Thrombectomy Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Atherectomy and Thrombectomy Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Bayer AG, Boston Scientific Corp., Covidien plc, Cardiovascular Systems Inc., and Spectranetics Corp.

Other vendors mentioned in the report are Argon Medical Devices Inc., Accellent Inc. AtheroMed Inc., C.R. Bard Inc., Cod Man Neuro, (DePuy Orthopaedics Inc.), Cook Medical Inc. Edwards Lifesciences Corp., IDEV Technologies Inc., Lazarius Effect, Medtronic Inc., NexGen Medical Systems Inc., Reverse Medical Corp., St. Jude Medical Inc., and Teleflex Medical Inc.

Click Here To Download Detail Report:

Key questions answered in this report:

    What will the market size be in 2018 and what will the growth rate be?
    What are the key market trends?
    What is driving this market?
    What are the challenges to market growth?
    Who are the key vendors in this market space?
    What are the market opportunities and threats faced by the key vendors?
    What are the strengths and weaknesses of the key vendors?

Table of Content

1. Executive Summary

2. List of Abbreviations

3. Scope of the Report

4. Market Research Methodology

5. Introduction

6. Global Atherectomy and Thrombectomy Market

7. Market Segmentation by Product Category

8. Geographical Segmentation

9. Global Atherectomy Market

10. Market Segmentation by Product Type

To Buy The Copy of This Report Visit:

11. Geographical Segmentation

12. Global Thrombectomy Devices Market

13. Market Segmentation by Procedure

14. Geographical Segmentation

15. Buying Criteria

16. Market Growth Drivers

17. Drivers and their Impact

18. Market Challenges

19. Impact of Drivers and Challenges

20. Market Trends

21. Trends and their Impact

22. Vendor Landscape

23. Key Vendor Analysis

24. Other Reports in this Series

Latest Reports:

Infectious Vaccines Partnering Terms and Agreements:        

The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Click Here To Download Detail Report:

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

    What is actually granted by the agreement to the partner company?
    What exclusivity is granted?
    What are the precise rights granted or optioned?
    What is the payment structure for the deal?
    How are sales and payments audited?
    What is the deal term?
    How are the key terms of the agreement defined?
    How are IPRs handled and owned?
    Who is responsible for commercialization?
    Who is responsible for development, supply, and manufacture?
    How is confidentiality and publication managed?
    How are disputes to be resolved?
    Under what conditions can the deal be terminated?
    What happens when there is a change of ownership?
    What sublicensing and subcontracting provisions have been agreed?
    Which boilerplate clauses does the company insist upon?
    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
    Which jurisdiction does the company insist upon for agreement law?

Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast – Global Analysis:                        

Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s disease drug market.

From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market.

Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market.

Click Here To Download Detail Report:

Present & Pipeline Drugs Studied in this Report

1.    Namenda

2.    Ebixa

3.    Axura

4.    Aricept

5.    Nootropil

6.    Exelon

7.    Memary

8.    Solanezumab

9.    LuAe58054

This report contains 10 chapters.

(Chapter 1): Executive Summary

(Chapter 2): This Chapter is divided into 2 parts

A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018

B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)

(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials

(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948



Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Zithromax Arrhythmia Allegations Lawyer: Resource4thePeople Announces No-Cost Consultations Will be Available over the Holidays

Zithromax Arrhythmia Allegations Lawyer: Resource4thePeople Announces No-Cost Consultations Will be Available over the Holidays

San Diego, CA (PRWEB) December 24, 2013

Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about legal options in connection with allegations involving life-threatening side effects from Zithromax and other azithromycin-based antibiotics.

The U.S. Food and Drug Administration identified these dangerous side effects, including arrhythmia and sudden death in a March 3, 2013 Health Warning* issued to health care professionals and consumers.

“We are proud to announce that our policy of providing complimentary consultations to consumers inquiring about these allegations and their legal options to seek compensation will not be interrupted by the holiday season,” said Resource4thePeople.

“In response to numerous inquiries from consumers who have asked about whether our attorneys will be available over the holidays we are announcing that our 24-hour hotline will be staffed for those who may be seeking legal options about their eligibility to seek compensation over these allegations.”

Resource4thePeople said that the health warning issued by the FDA has been generating increasing numbers of inquiries from consumers who may have been affected by these allegations and are requesting information about how to seek compensation for medical and other expenses.

The FDA describes Zithromax as a macrolide antibiotic used in the treatment of bacterial infections in many parts of the body and expresssed these concerns in the March 3, 2013 Health Warning* issued by the FDA addressed similar concerns:

“The U.S. Food and Drug Administration (FDA) is warning the public that azithromycin (Zithromax or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias. This communication is a result of our review of a study by medical researchers as well as another study by a manufacturer of the drug that assessed the potential for azithromycin to cause abnormal changes in the electrical activity of the heart.”

To aid consumers, Resource4thePeople’s national network of attorneys are reviewing claims that involve possible symptoms of arrhythmia, sudden death and other serious health allegations involving popular antibiotics such as Zithromax.

The medications involved are known generically as azithromycin, and are sold under names such as Zithromax, Zithromax Z-Pak, Zithromax Tri-Pak and Zmax.

The following are among health symptoms being reviewed by Resource4thePeople’s national network of attorneys:

    fast, pounding, or irregular heart beat






    wheezing or difficulty breathing or swallowing

    swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs


    mouth sores

    severe diarrhea (watery or bloody stools) that may occur with or without fever and stomach cramps (may occur up to 2 months or more after your treatment)

    yellowing of the skin or eyes

    extreme tiredness

    unusual bleeding or bruising

    lack of energy

    loss of appetite

    pain in the upper right part of the stomach

    flu-like symptoms

    dark-colored urine

    blisters or peeling of the skin

    unusual muscle weakness or difficulty with muscle control

The Canadian equivalent of the FDA, Health Canada, also issued a warning about Zithromax that was posted May 16, 2013.** It warned that “Prolonged cardiac repolarization and QT interval have been seen in treatment with macrolides including azithromycin. Health care practitioners should consider the risk of fatal cardiac arrhythmias with azithromycin when prescribing antibacterial treatment for patients who are already at risk for cardiovascular events.”

The FDA also sent a strongly worded warning letter*** on June 19, 2012 to the medications’ manufacturer, Pfizer Inc., over language federal officials described as “false” and “misleading” in a marketing brochure.

In its letter the FDA criticized a brochure issued by Pfizer for the medications and made the following finding:

“The brochure is false or misleading because it omits and minimizes important risk information, makes unsubstantiated superiority claims, omits material facts, broadens the indication for the drug product, makes misleading efficacy claims, and makes unsubstantiated claims for Zmax.”

FDA regulators also found that the brochure omitted important information that should have warned consumers about the risk of serious heart problems:

“Specifically, the brochure omits the important risk of QT prolongation associated with Zmax use. The WARNINGS AND PRECAUTIONS section of the PI states, “[p]rolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarization” (emphasis in original). By omitting this serious risk associated with Zmax, the brochure misleadingly suggests that the drug is safer than has been demonstrated.”





Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Looking for Late Christmas Presents? Sublime Beauty

Looking for Late Christmas Presents? Sublime Beauty® Offers Festive Boxes with Anti-Aging Serum On Sale and Ready to Give

St. Petersburg, FL (PRWEB) December 24, 2013

Better late than never. Sublime Beauty® offers great gift choices for that late gift, in a festive Christmas box with bow, ready to give. And they are on sale, too.

“Anyone who is interested in looking better, or quality skincare, will appreciate this gift,” says Kathy Heshelow, founder of Sublime Beauty®. “We include Collagen and Hyaluronic serums in a box, or add Retinol in a box of three serums- ready to give!”

The Sublime Beauty® Collagen serum is very popular, with the active ingredient Matrixyl®. Matrixyl boosts collagen production, an important element for youthful skin. We lose collagen each year, and this contributes to wrinkles, sagging and thinning of skin.

Studies published in Molecular Pharmaceutics magazine by Ian Hamsley this year showed that Matrixyl can double collagen production.

Hyaluronic serum works to plump and cushion skin, while Retinol is considered the workhorse of skincare routines. Retinol can reduce age spots, wrinkles, pores and hyperpigmentation; it helps to improve skin quality and also helps to promote collagen synthesis.

All Sublime Beauty® products are available through Amazon, with fast shipping and secure checkout. All late Christmas gifts can be seen on the Sublime Beauty® website gift page.

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Chaffin Luhana Honors the Spirit of Giving with New Foundation Website

Chaffin Luhana Honors the Spirit of Giving with New Foundation Website

New York, New York (PRWEB) December 25, 2013

The founding partners of Chaffin Luhana LLP, a national plaintiffs-only law firm, is pleased to announce the launch of a new website, The foundation reflects the efforts that Eric Chaffin, Roopal Luhana and the entire Chaffin Luhana LLP team make every year to support and uplift those who are facing difficult challenges in life.

“Our motto is Doing Good by Doing Right,” said partner Eric Chaffin, “and we take that very seriously. The new website outlines the activities, grants, and outreach projects we’re working on to give back to our communities and support those who really need it. Our efforts through the Foundation are some of our most rewarding, and we want to spread the word to both increase awareness about needy organizations and individuals, and to celebrate those who are overcoming hurdles and serving as great examples for the rest of us.”

A not-for-profit organization, the Chaffin Luhana Foundation encourages the development of human potential and supports community empowerment through the endowment of funds to deserving recipients, the creation of community-based enrichment projects, and the support of important scientific research that meaningfully impacts the underprivileged and sick in society.

Some highlights of the Foundation’s work so far include, among others:

University of Michigan Zinc Research: The Foundation made a substantial grant to the University of Michigan to assist in the research of how zinc reacts within the body. It is hoped that this research will result in better care and treatment for zinc-induced copper deficiency myeloneuropathy, a disorder that causes pain, weakness, and loss of body control, and which can occur as a result of long-term use of denture cream with high zinc content. This project grew out of the firm’s work on behalf of hundreds of unfortunate consumers who were permanently disabled from the zinc in denture adhesive.
Sarah Jane Brain Foundation: Founded by the father of a child who was shaken as an infant, this organization works to create a model system of care for children and young adults suffering from pediatric acquired brain injuries. The Chaffin Luhana Foundation made a sizable donation to the organization, which celebrated the life of Cheryl DelRossi, a former Chaffin Luhana client.
St. Joseph’s Soup Kitchen in New York City: The Foundation recently made a sizable donation to this organization over the Thanksgiving holiday, which feeds meals every Saturday to the homeless and the working poor. The Foundation donation provided meals to 650 needy New Yorkers.
NY Cares Annual Coat Drive: Chaffin Luhana staff and their families donated coats, and the Foundation purchased coats for the drive, which is facing a large shortage of donations this year. The coat drive raised 135 coats to help keep New York’s underprivileged warm during the winter months.
Habitat for Humanity: The Foundation made a significant donation, and staff members volunteered to help with the building of a home in the Westchester, New York area. The firm donated the staff time to the work day.
Newtown Kindness: The firm recently made a seed donation to Newtown Kindness on the eve of the one year anniversary of the Connecticut school shootings. This organization teaches school children and others to think kindly and act boldly. The mission of Newtown Kindness is aligned with the Chaffin Luhana firm, which has a motto of “Doing Good by Doing Right.”

The Foundation’s spokesperson is Para-Olympic medalist Stephani Victor, who suffered a traumatic car accident when she was only 26 years old that robbed her of both legs. She went on to become a Para-Olympic downhill skier, winning five medals in the last three Paralympic Winter Games, including a gold medal and two silver medals in 2010 in Vancouver. Though injuries kept her out of racing for nearly two seasons, she is staging a comeback for the Sochi 2014 Paralympic Winter Games.

Stephani is a former client of Eric and Roopal’s, and has been close friends with them for years. She shares their vision for encouraging accomplishment through the Chaffin Luhana Foundation, and will be involved in the Stephani Victor Legacy Award, which the Foundation plans to give to one deserving individual each year.

“I witnessed from a very early age what it takes to work hard and sustain yourself,” she says, “and I share the values that Roopal and Eric have—that when you come from a humble beginning, you never lose your connection to that. There’s a lot of good to be done, and I’m excited to be working with the Chaffin Luhana Foundation to make it happen.”

Chaffin Luhana LLP has a long and successful history of protecting the rights of those affected by adversity including those who have suffered from serious side effects caused by medical devices and pharmaceutical drugs. Partners Eric Chaffin and Roopal Luhana represent high-profile cases in federal and state courts across the country, and provide new online resource centers for clients and the public. To date, Mr. Chaffin and Ms. Luhana along with co-counsel have been involved in recovering over $ 1 billion for injured consumers. Both have been named to the prestigious New York Metro Super Lawyers list numerous times, and though unable to guarantee results, the firm has a distinguished track record of success and is highly committed to each case.


Eric T. Chaffin, Esq.


600 Third Avenue, 12th Floor

New York, NY 10016

Toll Free Telephone: (888) 480-1123

Toll Free Fax: (888) 499-1123

May be construed as Attorney Advertising in some states. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

New Pradaxa Lawsuit Alleges Gastrointestinal Bleeding: Now, AttorneyOne Can Provide Advice

New Pradaxa Lawsuit Alleges Gastrointestinal Bleeding: Now, AttorneyOne Can Provide Advice

Pradaxa: serious adverse events

San Diego, CA (PRWEB) December 24, 2013, a recognized authority on law, updated the website recently and they are now actively providing expert opinion in view of the recent news on Pradaxa Lawsuits.

On November 20, a new lawsuit was filed by a man in Missouri Eastern District Court (case no. 4:2013cv02335) alleging that he suffered gastrointestinal bleeding from Pradaxa. Pradaxa (dabigatran etexilate), manufactured by Boehringer Ingelheim Pharmaceuticals, is a new oral anticoagulant mainly used as a blood thinner for patients who are at risk for stroke or atrial fibrillation. In the lawsuit, the plaintiff claims that he was prescribed Pradaxa for long-term maintenance and in 2011, he suffered lower gastrointestinal bleeding.

As Bloomberg published on December 10, a US District Judge ordered Boehringer to pay $ 931,000 as a fine for withholding documents related to the Pradaxa Multidistrict Litigation (MDL No. 2385, U.S. District Court, Southern District of Illinois).

Taking into consideration the latest developments, updated the website and, now, can actively provide an expert opinion including how to get in contact with legal counsel easily and inexpensively in cases of severe complications, allegedly from Pradaxa. Sean Burke, director of Media Relations at, adds that the relevant information illustrates that people continue to file Pradaxa lawsuits. “For that reason,” he continues, “our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

Court data, updated on December 16, by the Judicial Panel on Multidistrict Litigation reveal that there are 1,883 cases pending in the Pradaxa MDL. has further information on Pradaxa lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website You can also find us on Facebook at Checkout earlier news from us at

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Global Knee and Hip Market 2013 Edition Research Report Now Available at

Global Knee and Hip Market 2013 Edition Research Report Now Available at

Market Reports Online

Dallas, TX (PRWEB) December 25, 2013

Knee and hip joints are the most important joints in the human body as they bear our body weight. Both knee and hip are large, complex joints that are frequently injured through sports, accidents and the aging process. In addition, conditions like arthritis and bursitis may also cause chronic pain. Advanced designs have led to the development of high joint stability and functionality, which provides a much better degree of movement. These technological advancements aim at returning the maximum degree of function to joints and have made surgery a more viable option for patients. Joint replacements surgery has been one of the greatest medical advances over the time. Complete report available at

Economic development and the corresponding increases in the disposable income, intensifying focus on health; rising demand for minimally invasive and other improved technological surgeries; and growing obesity rates are among the major factors driving the global knee & hip market. The market is projected to further grow in years to come and become more specialized due to economic, social and demographic trends.

The global knee & hip market is consolidated with top five players controlling the majority share of the total market. Zimmer, Johnson & Johnson (DePuy), Stryker, Biomet and Smith & Nephew are the leading players in the knee & hip market.

Order a copy of this report at

The report “Global Knee & Hip Market” analyzes the global and the US market. It also identifies the key trends shaping and driving the dynamism in knee & hip market. The report provides insight on the prevalent competitive landscape of major players, along with their business strategies.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Few Points From Table of Contents ( are listed below:

1. Introduction

1.1 Hip Disorders & Treatment

1.1.1 Hip Anatomy

1.1.2 Hip Disorders

1.1.3 Symptoms of Hip Disorder

1.1.4 Types of Hip Procedure

1.2 Knee Disorders & Treatment

1.2.1 Knee Anatomy

1.2.2 Knee Disorders

1.2.3 Symptoms of Knee Disorders

1.2.4 Type of Knee Procedures

2. Market Size

2.1 Global Orthopedic Market

Market Value

Major Segments

Regional Breakdown

2.2 Knee Market

2.2.1 Global Knee Market

Market Value

Market Growth

Price Trend

Regional Breakdown

2.2.2 The US Knee Market

Market Value

Market Volume

2.3 Hip Market

2.3.1 Global Hip Market

Market Value

Market Growth

Price Trend

Regional Breakdown

2.3.2 The US Hip Market

Market Value

Market Volume

3. Market Dynamics

3.1 Key Trends

3.1.1 Improved Implant Materials and Surgical Techniques

3.1.2 Drive towards Minimally Invasive Surgeries

3.1.3 Increasing Obesity Rate

3.2 Growth Drivers

3.2.1 Rise in Aging Demographics

3.2.2 Economic Development

3.2.3 Accelerating Healthcare Expenditure

3.3 Significant Developments

3.3.1 The Personalized Knee System by Zimmer

3.3.2 Empi Phoenix Muscle Stimulator by DJO Global

3.3.3 Exactech Introduces LPI Prime Hip System: A Conservative Treatment Hip Replacement System

3.3.4 CStem AMT Total Hip System by DePuy

3.4 Challenges

3.4.1 Regulatory risk

3.4.2 Dearth of Expertise and Trained Healthcare Workers

3.4.3 Inadequate Reimbursement and Coverage

4. Competitive Landscape

4.1 Competition in Orthopedic Market

4.2 Competitive Landscape Global Knee Market

4.3 Competitive Landscape Global Hip Market

5. Company Profiles

5.1 Johnson & Johnson DePuy

5.2 Zimmer

5.3 Stryker

5.4 Biomet

6. Market Outlook

6.1 Market Forecast

6.2 Forecast Methodology

6.2.1 Dependent and Independent Variables

6.2.2 Correlation Analysis

6.2.3 Regression Analysis

List of Tables

List of Charts

Explore more reports on Pharmaceuticals markets at

Related Reports:

Orthopaedics: Market Prospects & Global Competition ( In Orthopaedics: Market Prospects & Global Competition, Espicom focuses its attention on 49 of the companies that we believe is making significant inroads on their chosen area of orthopaedic specialty. This 2013 edition helps to build a bigger picture of the companies and some of their most relevant activities, giving insight into the current state of, and future prospects for, the market.

About Us: is an online database of regional industry research reports, company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the pharmaceuticals industry, offers research studies on agriculture, energy and power, chemicals, consumer goods, environment, food and beverages, healthcare, banking and financial services, medical devices and much more.

Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Yaz, Yasmin Blood-Clotting Allegation Lawyers: Resource4thePeople Announces No-Cost Consultations Will Be Available over the Holidays

Yaz, Yasmin Blood-Clotting Allegation Lawyers: Resource4thePeople Announces No-Cost Consultations Will Be Available over the Holidays

San Diego, CA (PRWEB) December 25, 2013

Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about legal options to seek compensation over allegations* that the popular contraceptives Yaz and Yasmin may cause life-threatening blood-clotting problems.

“We are proud to announce that our policy of providing free consultations to consumers inquiring about these allegations and their legal options to seek compensation will not be interrupted by the holiday season,” said Resource4thePeople.

The announcement was made after numerous inquiries were made by consumers about whether the Resource4thePeople national network of attorneys would be available over the holiday season to provide legal options to those affected by allegations contained in Yaz and Yasmin (drospirenone) lawsuits,* said Resource4thePeople.

“We have been seeing a steady increase in the number of consumers inquiring about alleged Yaz and Yasmin (drospirenone) side effects since the Food and Drug Administration issued a Health Warning** about possible blood-clotting dangers.”

In its April 10, 2012 Health Warning, FDA officials said the agency had conducted a review and “has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.”

There are currently nearly 10,000 lawsuits from across the country containing allegations Yaz and Yasmin may cause life-threatening blood-clotting problems currently consolidated before a single federal court judge.

Those figures*** were compiled by the U.S. Judicial Panel on Multidistrict Litigation and show that as of the end of the latest reporting period — Nov. 18, 2013 — there were 9,837 Yaz and Yasmin lawsuits in the multidistrict litigation.

Some of these lawsuits are being settled, according to a recent financial report**** from pharmaceutical giant Bayer, the manufacturer of Yaz and Yasmin contraceptives. It shows that the company has agreed to pay out nearly $ 1.6 billion so far to settle cases in the huge U.S. federal court multidistrict litigation.*

The progress of the settlements was recently reported to Judge David R. Herndon, in the U.S. District Court in the Southern District of Illinois, at a Nov. 14, 2013 status hearing.

The figures about legal costs involving thousands of lawsuits alleging that the contraceptives have caused life-threatening blood-clotting problems were detailed in pharmaceutical giant Bayer’s stockholder newsletter for the third quarter of 2013.

The massive payoffs were included in the Oct. 31, 2013 posting informing investors about the financial progress of the company, including an update of its legal costs.

“This is a huge amount of money and shows the extent of how significant the allegations about blood-clotting made by thousands of women are and how they are being compensated for a possibly fatal condition,” said Resource4thePeople.

In the third quarter financial report Bayer reported the following details:

“As of October 18, 2013, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 7,660 claimants in the U.S. for a total amount of about US$ 1.575 billion. Bayer has only been settling claims in the U.S. for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case-specific analysis of medical records on a rolling basis. Such injuries are alleged by about 2,300 of the pending unsettled claimants. Bayer will continue to consider the option of settling such individual lawsuits in the U.S. on a case-by-case basis.”

Bayer also has agreed to pay up to $ 24 million to settle other lawsuits in the multidistrict litigation involving allegations over gall bladder side effects, according to the court file in the litigation.

These settlements are a different component of this consolidated litigation in Illinois in which plaintiffs claimed that they suffered gall bladder injuries because they used Yaz and Yasmin as contraceptives.

Meanwhile, as a Sept. 15, 2013 article***** in the Chicago Tribune points out, federal officials are being asked to escalate warnings about possible blood-clotting problems associated with the contraceptives and at least one consumer non-profit organization has called for the products to be pulled from the marketplace.

“The concerns raised by women’s and consumer groups center focus on the same allegations made in the Yaz and Yasmin lawsuits — that the use of these birth control pills may pose life-threatening side effects to the women who use them,” said Resource4thePeople.

The Chicago Tribune article questioned the effectiveness and safety of Yaz and Yasmin contraceptives and cited increased concern about the products from women’s groups:

“Some women’s health advocates want a stronger, black-box warning that is more likely to be noticed,” the Tribune reported. “The advocacy group Public Citizen, meanwhile, has placed drugs containing drospirenone — including Yaz, Yasmin, Gianvi and Zarah — on its ‘do not use’ list because they ‘can cause increased blood levels of potassium and (are) no more effective than other oral contraceptives in preventing pregnancy.’ On the Internet, people who call themselves ‘Yaz survivors’ post accounts of their experiences.”

In a related matter, the Canadian Broadcasting Company reported that physicians there are linking Yaz and Yasmin to 23 deaths. In a June 12, 2013 posting***** The CBC said that “According to documents obtained from Health Canada, doctors and pharmacists say Yaz and Yasmin are suspected in the deaths of the women, who mostly died suddenly from blood clots.”

Health Canada is the Canadian equivalent to the FDA, which, on April 10, 2012, issued a Health Warning informing consumers and physicians about possible Yaz and Yasmin blood clotting side effects.******


*In re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation MDL No. 2100, U.S. District Court, Southern District of Illinois






Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.